Results 281 to 290 of about 87,925 (315)

Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research.

Dis Model Mech
Sutter L, De Cock L, Wang CC, Gorgels D, Wyns K, Verbeeck K, Vanleeuw U, Douchy T, Hompes D, Jaekers J, Van Raemdonck D, Vanden Bempt I, Debiec-Rychter M, Sciot R, Wozniak A, Schöffski P.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Imatinib and Pregnancy

Journal of Clinical Oncology, 2006
Abstract Animal studies with imatinib have shown it to be teratogenic, embryotoxic and to result in increased rates of post-implantation loss. As a consequence there are justifiable physician/patient concerns regarding the safety of tyrosine kinase inhibitors during pregnancy.
Ali, RIDVAN, Ozkocaman, VİLDAN, Ozkan, Atilla, Ozcelik, Tulay, Ozkalemkas, Fahir   +4 more
openaire   +5 more sources

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Journal of Clinical Oncology, 2003
PURPOSE Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.
M. Heinrich, C. Corless, G. Demetri, C. Blanke, M. von Mehren, H. Joensuu, Laura S. McGreevey, Chang-jie Chen, A. D. Van den Abbeele, B. Druker, B. Kiese, B. Eisenberg, P. Roberts, S. Singer, C. Fletcher, S. Silberman, S. Dimitrijević, J. Fletcher   +17 more
semanticscholar   +1 more source

Imatinib

Drugs, 2001
Imatinib inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukaemia (CML). Complete haematological responses were achieved in 88% of patients and major cytogenetic responses were detected in 49% of patients with chronic phase CML treated with oral imatinib 400 mg/day in a multicentre noncomparative ...
K, Lyseng-Williamson, B, Jarvis
openaire   +2 more sources

Imatinib and Hyperlipidemia

New England Journal of Medicine, 2005
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M, MANZATO, ENZO, GHERLINZONI F.   +2 more
openaire   +3 more sources

Imatinib, cheese and migraines

Leukemia & Lymphoma, 2020
Here we report a patient with maculopapular cutaneous mastocytosis who developed imatinib-induced cheese sensitivity manifest as migraine headaches.
Michael Woodfin, Laura Bickel, Laura Bickel, Michael W. Deininger, Michael W. Deininger   +4 more
openaire   +3 more sources

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Science, 2004
Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.
N. Shah, C. Tran, F. Lee, Ping Chen, Derek J. Norris, C. Sawyers   +5 more
semanticscholar   +1 more source

Imatinib-induced pseudoporphyria

Clinical and Experimental Dermatology, 2009
Imatinib, a synthetic tyrosine kinase inhibitor, is used as first-line therapy for chronic myeloid leukaemia. Imatinib treatment is associated with a variety of adverse effects, most of which are mild to moderate and generally abate after the first months of treatment.
Timmer-de Mik, L., Kardaun, S.H., Kramer, M.H.H., Hayes, D., Bousema, M.T.   +4 more
openaire   +4 more sources

Imatinib Mesylate

2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Ahmed H. Bakheit, Badraddin M.H. Al-Hadiya, Ahmed A. Abdelgalil   +2 more
openaire   +3 more sources

Imatinib resistance in CML

Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
VOLPE, Gisella, Panuzzo C, Ulisciani S, CILLONI, Daniela   +3 more
openaire   +4 more sources